Literature DB >> 2254623

Branched chain amino acids in the management of chronic liver disease. Facts and fantasies.

M Y Morgan1.   

Abstract

The liver plays a central role in protein and amino acid metabolism. It processes dietary amino acids and reprocesses amino acids released from muscle protein degradation. It utilises amino acids for protein synthesis and gluconeogenesis, regulates the supply of amino acids to peripheral tissues and converts excess amino acids to urea. In patients with liver disease the liver's ability to control both plasma and tissue amino acid fluxes may be seriously disturbed. The resultant changes in amino acid metabolism may be implicated in the genesis of the neuropsychiatric abnormalities and the deterioration in nutritional status commonly observed in patients with hepatic failure. Thus, on theoretical grounds, amelioration of these amino acid abnormalities might benefit patients with liver disease who have hepatic encephalopathy or are malnourished. However, there is, at present, no consensus as to the efficacy, practicality or cost-effectiveness of 'amino acid therapy' in patients with liver disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254623     DOI: 10.1016/0168-8278(90)90103-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

1.  Dietary management of hepatic encephalopathy.

Authors:  C A Seymour; K Whelan
Journal:  BMJ       Date:  1999-05-22

Review 2.  Nutritional support for liver disease.

Authors:  Ronald L Koretz; Alison Avenell; Timothy O Lipman
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Effects of a branched-chain amino acid-enriched diet on chronic hepatic encephalopathy in dogs.

Authors:  H P Meyer; R A Chamuleau; D A Legemate; J A Mol; J Rothuizen
Journal:  Metab Brain Dis       Date:  1999-06       Impact factor: 3.584

Review 4.  Pharmacotherapy for hepatic encephalopathy.

Authors:  Paula V Phongsamran; Jiwon W Kim; Jennifer Cupo Abbott; Angela Rosenblatt
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

Review 5.  Hepatic Encephalopathy: From the Pathogenesis to the New Treatments.

Authors:  Juan Cordoba
Journal:  ISRN Hepatol       Date:  2014-06-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.